2 Reasons It's Not Too Late to Buy BioNTech

If you had bought $10,000 in BioNTech (NASDAQ: BNTX) on the date of its IPO in Oct. 2019, your investment would be worth well over $68,820 as of Dec. 16. There is one key reason for the spectacular run-up. BioNTech and its development partner, Pfizer (NYSE: PFE), successfully developed a coronavirus vaccine (BNT162b2) and received emergency use authorization from the U.S. Food and Drug Administration on Friday, Dec. 11.

This is the first-ever coronavirus vaccine in the U.S. to both have late-stage efficacy data and enter the public sphere via regulatory clearance. Right now, many investors are checking out Pfizer's stock due to its consistent revenues, sturdy profit margins, dividend payout, and long-standing status as a giant in the pharma industry. I think that, however, BioNTech would better suit growth investors looking for bigger gains. Here are two reasons why.

Image source: Getty Images.

Continue reading

Source Fool.com